A human monoclonal antibody against interleukin-2 receptor on activated lymphocytes for reducing the risk of rejection in transplantation.
Decreases the risk of rejection in renal transplants without an increase in the risk of infection.
Reduces rejection rate in cardiac transplant but is associated with an increased infection rate when concomitant cytotoxic agents are used.
Inhibits proliferation of T cells with an immunosuppressive effect.
Half life is approximately 20 days.
Approved as Zinbryta.
Approved as a once monthly self administered subcutaneous injection for the treatment of adults
Can cause severe liver injury including life-threatening events, liver failure, and autoimmune hepatitis.
Immune mediated disorders including skin reactions, lymphadenopathy colitis and other immune mediated disorders can occur.
A once monthly self administered subcutaneously injection also indicated for the treatment of adult patients with relapsing forms of multiple sclerosis.
The multiple sclerosis this drug binds to and blocks IL2RA.